Neuronetics Inc

STIM remains in a Stage 2 advance within its medium-term uptrend, though the long-term downtrend persists. A Bullish Exhaustion pattern at recent highs signals waning momentum. Price is now pulling back into the rising 9EMA and 21EMA support zone while overbought pressures have eased. This pullback offers a speculative entry aligned with the medium-term bullish bias. Key risks include a deeper decline if EMAs fail to hold and continued Stage Transition Risk into Stage 3.

• ↑Q1 revenue reached $34.5M (+8% YoY), with U.S. clinic sales up 15%.
• ↑Cost measures to yield $2.5–3M annual savings from Q3, cash at $19M.
• ↓Gross margin fell to 46.9% vs. 49.2% YoY, pressuring earnings.